The weekly litigation news digest is live. Subscribe now
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure - EP4212152
The patent EP4212152 was granted to Novartis on Apr 30, 2025. The application was filed on May 9, 2016 under application number EP23154757A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4212152
- Application Number
- EP23154757A
- Filing Date
- May 9, 2016
- Status
- Granted And Under Opposition
- Mar 28, 2025
- Publication Date
- Apr 30, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
A dosage regimen for the treatment of chronic systolic heart failure with reduced ejection fraction in a human patient. The regimen involves initiating therapy with a sacubitril and valsartan combination in a 1:1 molar ratio, with the starting dose being 50 mg of sacubitril and valsartan in a 1:1 molar ratio. The therapy is titrated over 12 weeks to achieve and maintain a target dose of 200 mg twice daily. The regimen is further extended to a target dose of 200 mg twice daily after 4 weeks of titration.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (8) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents